Beyond the Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Bladder Cancer

Sunday, April 30, 2023

7:30 AM – 10:00 AM CST

Location: S100BC

Moderator(s)

Arlene O. Siefkerradtke, MD

Professor
MD Anderson Cancer Center

Faculty(s)

Siamak Daneshmand, MD

Professor of Urology, Director of Urologic Oncology
University of Southern California
Joshua J. Meeks, MD (he/him/his)

Northwestern University
Matthew I. Milowsky, MD

University of North Carolina at Chapel Hill
JW

J. A. Witjes, MD (he/him/his)

Radboud University Medical Center

Part 1 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the American Urological Association Annual Meeting 2023 (AUA2023)

Activity Website:
To Register For This Complimentary Event, Visit:
http://www.researchtopractice.com/Meetings/AUA2023

This activity is offered for in-person and virtual AUA conference attendees.

CME provided by Research To Practice

This activity is supported by educational grants from Bristol-Myers Squibb Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Location:
McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616

Program Schedule — Central Time
7:30 AM – 8:00 AM — Registration
8:00 AM – 10:00 AM — Breakfast Meeting

Meeting Room:
Grand Ballroom (S100) – Level 1, South Building

This 2-hour CME-accredited in-person symposium and live webcast, part 1 of a 2-part series, will focus on the management of patients with urothelial bladder cancer. Research To Practice (RTP) will recruit five clinical investigators with an expertise and/or specialized interest in the management of urothelial bladder cancer to serve as the faculty, one of whom will moderate the program.

To support the theme of the project, in the first quarter of 2023 RTP will recruit 17 US-based and international urologic oncology clinical investigators who, in addition to the invited faculty members, will participate in a unique educational assessment. As part of the assessment, each investigator will be asked to complete a survey consisting of approximately 50 case-based and related management questions intended to illuminate their general practice patterns related to the treatment of patients with urothelial bladder cancer. At the conclusion of the assessment, RTP will aggregate and analyze all of the investigator-provided information in order to prioritize key topics and identify interesting data points and patient care issues for inclusion in the live event. For each data point selected for inclusion, a custom-designed slide will be created to anonymously illustrate the preferred treatment or related response from each faculty member and the other 17 surveyed investigators.

During the live meeting, in person clinician attendees will be provided networked iPads to participate in interactive polling which will include a number of the same questions posed as part of the premeeting investigator survey. Virtual attendees will be able to complete the same survey on our Zoom platform. Throughout the symposium, results of the interactive audience polling will be juxtaposed with the findings from the investigator survey to observe educational gaps and establish a framework for discussion. Each faculty member will also be asked to prepare and deliver an approximately 10-minute presentation focused on reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the survey. Following each of the faculty presentations, moderated panel discussion and the introduction of additional findings and trends observed from the investigator assessment will ensue to generate other relevant perspectives and dialogue. Clinicians will also be encouraged to use the iPads throughout the event to submit additional questions. The moderator will incorporate a number of these queries into the panel discussions in order to stimulate additional debate.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A CME credit link will be given to each participant at the conclusion of the activity.

Learning Objectives:

Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
Evaluate the FDA-approved indication for adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic UBC.
Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
Appreciate the biologic rationale for combining anti-PD-1/PD-L1 antibodies with other systemic agents with established efficacy in UBC, and assess the current and potential roles of these regimens in patient care.
Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.